Patricia Morgan

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial”.

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

The Lancet(2023)10.1016/s0140-6736(22)02400-x

N/A

4.3DataRank · unranked

65 citations

Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Christine Lee, Anne Preston +50 more

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

New England Journal of Medicine(2022)10.1056/nejmoa2203067

N/A

3.6DataRank · unranked

125 citations

Azza H. Idris, Nina M. Berkowitz, Myra Happe, Martin R. Gaudinski, Christian Buettner +42 more

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

The Lancet Infectious Diseases(2022)10.1016/s1473-3099(22)00052-4

N/A

1.1DataRank · unranked

39 citations

Srilatha Edupuganti, Grace Chen, Myra Happe, Larisa Strom, Alicia T. Widge +67 more

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

The Lancet Infectious Diseases(2023)10.1016/s1473-3099(23)00344-4

N/A

1.0DataRank · unranked

24 citations

Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Prossy Naluyima, Francis Kiweewa +70 more

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults

The Lancet HIV(2025)10.1016/s2352-3018(25)00041-4

N/A

0.335DataRank · unranked

8 citations

Katherine V. Houser, Martin R. Gaudinski, Alicia T. Widge, Seemal F. Awan, Cristina Carter +95 more

Prenatal phenotyping: A community effort to enhance the Human Phenotype Ontology

American Journal of Medical Genetics Part C Seminars in Medical Genetics(2022)10.1002/ajmg.c.31989

N/A

0DataRank · unranked

52 citations

Patricia Morgan, Bimal P. Chaudhari, Isabel Filges, Teresa N. Sparks, Pablo Lapunzina +31 more

Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014

Journal of the Pediatric Infectious Diseases Society(2023)10.1093/jpids/piad078

N/A

0DataRank · unranked

3 citations

Linda Aurpibul, Brookie M. Best, Xiang Li, Meredith G. Warshaw, Hong Wan +54 more

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

npj Vaccines(2024)10.1038/s41541-024-00959-0

N/A

0DataRank · unranked

21 citations

Amelia R. Hofstetter, Pamela Costner, LaSonji A Holman, Cynthia S. Hendel, Alicia T. Widge +95 more

Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1–Exposed Newborn Infants

The Journal of Infectious Diseases(2021)10.1093/infdis/jiab229

N/A

0DataRank · unranked

51 citations

Coleen K. Cunningham, Petronella Muresan, Edmund V. Capparelli, Charlotte Perlowski, Patricia Morgan +44 more